Top in rheumatology: FDA approval of Cortophin Gel, retinopathy in patients with lupus
Click Here to Manage Email Alerts
The FDA recently approved Cortrophin Gel for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases. It was the top story in rheumatology last week.
Another top story covered data showing that more than 15% of newly diagnosed patients with systemic lupus erythematosus had evidence of retinopathy.
Read these and more top stories in rheumatology below:
FDA approves Cortrophin Gel for rheumatoid arthritis, multiple sclerosis
The FDA has approved a supplemental new drug application for ANI Pharmaceutical’s Cortrophin Gel to treat rheumatoid arthritis, multiple sclerosis and certain other autoimmune diseases, according to a company press release. Read more.
More than 15% of newly diagnosed patients with lupus exhibit evidence of retinopathy
Patients with systemic lupus erythematosus demonstrate a relatively high rate of retinopathy at initial diagnosis, and may represent an early manifestation of the disease, according to data published in BMC Rheumatology. Read more.
Most rheumatologists say COVID-19 pandemic exposed mental health as 'key unmet need'
In a recent survey of rheumatologists, 83% reported that the COVID-19 pandemic has revealed mental health support as a “key unmet need” among their patients, according to a report published by Cardinal Health. Read more.
Serious infection risk with TNF inhibitors ‘significantly lower’ in PsA vs. RA
Among patients treated with TNF inhibitors, the risk for serious infection was “significantly lower” in those with psoriatic arthritis compared with rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases. Read more.
B-cell therapies, mycophenolate worsen COVID-19 vaccine response in inflammatory disease
Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter. Read more.